avb6 integrin expression is upregulated on a wide range of epithelial tumours, and is thought to play a role in modulating tumour growth. Here we describe a human therapeutic antibody 264RAD, which binds and inhibits avb6 integrin function. 264RAD crossreacts with human, mouse and cynomolgus monkey avb6, and inhibits binding to all ligands including the latency-associated peptide of TGF-b. Screening across a range of integrins revealed that 264RAD also binds and inhibits the related integrin avb8, but not the integrins a5b1, avb3, avb5 and a4b1. In vitro 264RAD inhibited invasion of VB6 and Detroit 562 cells in a Matrigel invasion assay and avb6 mediated production of matrix metalloproteinase-9 in Calu-3 cells. It inhibited TGF-b-mediated activation of dermal skin fibroblasts by preventing local activation of TGF-b by NCI-H358 tumour cells in a tumour cell À fibroblast co-culture assay. In vivo 264RAD showed dose-dependent inhibition of Detroit 562 tumour growth, regressing established tumours when dosed at 20 mg/kg once weekly. The reduction in growth associated with 264RAD was related to a dose-dependent inhibition of Ki67 and phospho-ERK and a reduction of avb6 expression in the tumour cells, coupled to a reduction in fibronectin and alpha smooth muscle actin expression in stromal fibroblasts. 264RAD also reduced the growth and metastasis of orthotopic 4T1 tumours. At 20 mg/kg growth of both the primary tumour and the number of metastatic deposits in lung were reduced. The data support the conclusion that 264RAD is a potent inhibitor of avb6 integrin, with some activity against avb8 integrin, that reduces both tumour growth and metastasis.
INTRODUCTION
The integrin avb6 is an epithelial restricted transmembrane cell surface receptor that has a role in promoting a number of different pathologies, including cancer and fibrosis. It is a dimeric receptor, consisting of an a and a b subunit, that binds the extracellular matrix proteins fibronectin and tenascin. [1] [2] [3] In addition, it binds the latency-associated peptide (LAP) of TGF-b1 and -b3 with high affinity, and activates TGF-b. 4 In each ligand it engages an integrin binding motif Arg À Gly À Asp (RGD). [1] [2] [3] 5 In normal tissues expression is tightly regulated; however, avb6 is upregulated in subsets of a wide range of epithelial-derived cancers. Increased expression was originally noted in oral squamous carcinoma, 6, 7 where avb6 was associated with tumours of greater invasive potential. These observations extend to other solid tumours, including pancreatic, colon, ovarian, breast and lung cancer. [8] [9] [10] [11] [12] In these diseases patients showing highest avb6 expression have poor prognosis.
Increased expression of avb6 in tumour cells is associated with activation of a number of pathways. avb6 engagement increases ERK activation, 13 and the secretion of proteases MMP-2 (matrix metalloproteinase-2), -9 and UPA (urokinase-type plasminogen activator). [13] [14] [15] [16] [17] Moreover, it drives epithelial-to -mesenchymal transition and the invasive and metastatic potential of cells. [18] [19] [20] [21] avb6 expression is dynamically regulated with increased expression at the invasive edge of the tumour. 22, 9 One of the key physiological functions of avb6 is the regulation of local TGF-b pathway activation. TGF-b forms a dimer constrained into an inactive form by the association with TGF-b LAP. avb6 releases this constraint, enabling TGF-b to bind TGF-b-RII on adjacent cells; 4, 23 therefore, increasing avb6 enables tumour cells to modulate TGF-b in a paracrine manner. 24, 19 TGF-b signalling in the tumour microenvironment is pleiotropic; in some tumours it acts as a tumour suppressor, while in more advanced tumours TGF-b activation promotes tumour growth and metastasis. In other disease states aberrant activation of TGF-b by avb6 has been associated with the development of fibrotic diseases such as kidney and liver fibrosis, and lung disease, and this fibrosis is reduced by avb6 inhibition. [25] [26] [27] [28] [29] [30] In a pre-clinical tumour model, blocking the receptor with the human therapeutic antibody 3G9 reduces tumour growth. 31 avb6 is functionally related to avb8 integrin, interacting with TGF-b LAP. 32, 33 Less is known about avb8 function, particularly in tumours. Like avb6, avb8 binds TGF-b-LAP through the integrin binding motif, and activates the TGF-b-mediated signalling cascade. [32] [33] [34] avb8 has been implicated as a tumour suppressor in certain glioblastoma lines, 35 with downregulation increasing tumour growth. It is also associated with the regulation of developing vasculature in the embryonic brain, ablation of expression resulting in embryonic lethality through vascular malformations 35 and induced ablation in the adult resulting in brain arteriovenous malformation related pathology. 36 Here we describe a novel human therapeutic antibody 264RAD, which inhibits avb6 integrin with additional activity, versus avb8 integrin, which modulates tumour growth and metastasis.
RESULTS

264RAD binds and inhibits avb6 integrin
The SLAM technique in Xenomouse animals 37 was used to identify a panel of individual B-cells expressing human avb6 reactive antibodies from animals immunised with Chinese hamster ovary cells expressing human avb6. Sixteen antibodies were cloned by PCR and expressed as recombinant human immunoglobulin G1 (IgG1) antibodies. The antibodies were screened for specific binding to avb6, inhibition of avb6 mediated adhesion and selectivity over the related integrin a5b1, avb3 and a4b1 (Barry and Foltz, unpublished data). This identified antibody 264, which bound to purified human avb6 heterodimer and inhibited binding of purified avb6 to TGF-b LAP (data not shown), consistent with direct binding to the receptor. The CDR3 of this antibody consisted of the amino-acid sequence 'VETGRGDYHFYAMDV', which contains the common integrin binding motif RGD. Some low-affinity binding to other receptors was observed by fluorescence activated cell sorting (FACS); therefore, to reduce the potential of low-affinity interaction with other integrins, point mutations were made in the CDR3 to remove the RGD site. Mutating the glycine to alanine resulted in an antibody with the CDR3 'VETGRADYHFYAMDV', named 264RAD; it retained binding to avb6, but showed no low-affinity binding to other receptors by FACS. Importantly, the 264RAD mutant has similar potency compared to the parent antibody 264 (Supplementary Table 1) .
To specifically assess the interaction of 264RAD with avb6, K562 cells were stably transfected with human avb6. K562 cells were selected, as they only express a5b1 integrin. 38 Immobilised 264RAD bound K562 avb6 cells ( Figure 1a) . As a positive control the b6 blocking antibody 10D5 and the b1 blocking antibody 4B4 were included. Binding was specific for avb6 integrin, as control un-transfected K562 cells did not bind 264RAD (Figure 1b) . 264RAD also inhibits the ability of K562 avb6 cells to bind recombinant TGF-b LAP (Figure 1c ). 264RAD did not inhibit avb3/ b5-mediated binding to vitronectin, while L230 an av blocking antibody, reduced adhesion (Figure 1d ). 264RAD did not inhibit a5b1-mediated binding to fibronectin, while IIA1 an a5 blocking antibody, reduced adhesion (Figure 1e ). 264RAD did not inhibit a4b1 binding to CS-1, while 4B4 a b1 blocking antibody reduced adhesion (Figure 1f) .
To confirm selectivity for cells expressing endogenous avb6, binding to a panel of cell lines was determined. Cells were selected based on the differential expression of ITGB6, ITGB8, ITGB5, ITGAV, ITGB3, ITGA5 and ITGA4 (Supplementary Table 2) . Colo205, HT29, MBA-MB-231, NCI-H2122 and NCI-H358 express avb6, as confirmed by binding to the b6 blocking antibody 10D5 (Figure 1g ). 264RAD is bound to each of these cell lines (Figure 1g ). MDA-MB-231 and NCI-H1299 did not bind 10D5, suggesting lack of b6 expression. 264RAD did not bind these cell lines. As an additional control, human umbilical vein endothelial cells were included as an avb6 null cell type that expresses av integrins. 264RAD did not bind human umbilical vein endothelial cells, providing further evidence of the selectivity (Figure 1g ). 264RAD inhibits human, mouse and cynomolgus monkey avb6 avb6 potency was determined using cell-based assays. In a cell-based adhesion assay, 264RAD was significantly more potent than 10D5, a commercially available avb6 blocking antibody (Supplementary Figure 1) , 264RAD bound avb6 on cells with an affinity of o10 pM. To compare binding of 264RAD to human, murine and cynomolgus monkey avb6 in the same cellular background, we stably overexpressed each respective species homologue of both av and b6 integrin in K562 cells to generate species-specific heterodimers. K562 cells did not express human av integrin. 264RAD bound human, murine and cynomolgus monkey avb6 integrin heterodimer (Figure 2a ). 264RAD did not bind untransfected K562 cells (data not shown), consistent with the data presented in Figure 1 . To determine whether 264RAD was able to inhibit binding of human, murine and cynomolgus monkey avb6 to glutathione-S-transferase-TGF-b LAP, a cell-based adhesion assay was used (Figures 2b À d) . 264RAD is active against all three avb6 homologues.
264RAD binds and inhibits avb8 integrin The b6 chain of avb6 is related to another integrin b8 which also binds TGF-b LAP.
32 264RAD also bound K562 cells expressing human avb8 by FACS (Figure 3a) . avb6-and avb8-expressing K562 cell binding to 264RAD-coated plates was assessed (Figure 3b ). 264RAD bound both avb6 and avb8 overexpressing cells. 264RAD also inhibited the binding of K562 cells overexpressing avb6 and avb8 to immobilised glutathione-S-transferase-TGF-b LAP ( Figures  3c and d) ; however, 264RAD consistently did not give full inhibition of binding (Figure 3d ). 264RAD binds and inhibits both avb6 and avb8 integrins.
264RAD inhibits tumour cell invasion and MMP-9 secretion in vitro and activation of TGF-b in a co-culture assay Increased avb6 expression increases the invasive potential of tumour cells in vitro. At 1 mg/ml 264RAD markedly reduced the invasion of VB6 cells 16 through Matrigel (Figure 4a ). 264RAD was more effective against Detroit 562 cells, giving full inhibition down to 1 mg/ml (Figure 4b ). The potential for co-expression of avb6 and avb8 integrin was assessed across a number of tumour cell lines. Owing to a lack of appropriate antibodies to assess expression of b8 protein, expression was determined by reverse transcriptasequantitative PCR (Supplementary Figure 2) . Detroit cells also express ITGB8; therefore, it is possible that 264RAD also modulates avb8 function in this line. avb6 has previously been shown to modulate protease production. [13] [14] [15] [16] [17] When present at 10 mg/ml 264RAD reduced the accumulation of MMP-9 in Calu-3 conditioned media as determined by enzyme-linked immunosorbent assay (Figure 4c ). avb6 and avb8 integrins have a pivotal role in modulating activation of TGF-b. 4, 32, 33 264RAD in the presence or absence of latent TGF-b reduced both basal and induced pSmad3 levels in Detroit 562 cells (Supplementary Figure 4) . To assess modulation of TGF-b further a co-culture system was used. Co-culturing tumour cells with fibroblasts induces alpha smooth muscle actin (a-SMA) expression via TGFb-mediated mechanisms. 19 Culturing NCI-H358 with fibroblasts induced activated a-SMA-positive fibroblasts (Figures 4c, i , and iii). This activation was inhibited by both a small-molecule inhibitor of Alk-5 (TGF-b RII) (Figure 4c , iv) and 264RAD (Figure 4c ,ii), demonstrating effective inhibition of TGF-b activation. 264RAD inhibited activation of TGF-b mediated by NCI-H358 cells at concentrations as low as 80 ng/ml (Figure 4d ). Although we have confirmed that NCI-H358 express avb6, avb8 expression is unknown. NCI-H358 had detectable ITGB8 mRNA suggesting the potential to express b8 integrin, although lower than Detroit 562 cells (Supplementary Figure 2) . Although we cannot exclude that avb8 makes some contribution to the activation of fibroblasts by NCI-H358 cells, downregulating b6 expression by small interfering RNA treatment of the co-culture abrogated a-SMA activation in both relatively high (Calu-3) and low NCI-H358 ITGB8-expressing lines (Supplementary Figure 3) . 264RAD inhibits growth of Detroit 562 tumours Detroit 562 tumour xenografts are dependent on avb6 as growth is inhibited by the b6-specific antibody 3G9. 31 First the expression of avb6 and avb8 was assessed; Detroit 562 cells expressed To test the selectivity over avb3/b5 integrins, the ability of 264RAD to block A375M adhesion to plates coated with vitronectin was tested. Cells were incubated with IgG1 isotype control, 264RAD, 10D5 (b6) and L230 (av) at 0.5 mg/ml, and adhered at 37 1C for 40 min (d). To test the selectivity over a5b1 integrin, the ability of 264RAD to block K562 adhesion to plates coated with GST-FN 8-10 was tested. Cells were incubated with IgG1 isotype control, 264RAD, IIA1 (a5) at 5 mg/ml, and adhered at 37 1C for 40 min (e). To test the selectivity over a4b1 integrin, the ability of 264RAD to block K562 adhesion to plates coated with CS-1 was tested. Cells were incubated with IgG1 isotype control, 264RAD, 4B4 (b1) at 5 mg/ml, and adhered at 37 1C for 40 min (f ). To assess cell binding, 264RAD and a range of integrin antibodies were immobilised on the plate (at 1 mg/ml). Cells were allowed to bind to antibodies for 30 min at RT. Green represents strong binding and red represents no binding (g). The data are representative of more than two similar experiments. (Figure 7c ). These data demonstrate that in addition to having potential to target the growth of primary tumours, treatment with 264RAD is associated with reduced metastasis.
DISCUSSION
264RAD is a potent inhibitor of avb6 that also modulates avb8 but does not bind or inhibit avb3, avb5, a4b1 or a5b1. The binding of 264RAD is influenced by features in the heavy chain CDR3, which consists of the amino acids 'VATGRADYHFYAMDV'. 264RAD
contains a motif RADYxxY in the CDR3 (RGDYxxY in the parent antibody) that is critical for binding, as a RTD mutant was unable to bind avb6 (unpublished data). The motif is similar to peptides derived from the foot and mouth virus, and the integrin binding motif in TGF-b LAP that has the canonical binding sequence RGDLxxL 41, 42, 12, 5 and that also binds avb8. [32] [33] [34] It is surprising that 264RAD can tolerate an alanine-to-glycine mutation retaining binding activity, as this often abrogates binding to RGDdependent integrins. Although not tested in the current study, the tyrosine residues may also contribute to the selectivity of the antibody, holding the RAD motif in the correct conformation for binding.
The in vitro properties of 264RAD show the potential to reduce local cell invasion and metastasis by inhibiting protease production and cell invasion. This cell invasion is mediated by avb6 integrin in both lines, as invasion of VB6 is induced by overexpression of avb6, whereas the invasion of Detroit 562 cells was abrogated by the specific avb6 blocking antibody 10D5 (unpublished data). 264RAD also inhibited integrin-mediated activation of TGF-b measured in a tumour cell À fibroblast co-culture assay, reducing the induction of a tumour cellconditioned fibroblast phenotype. This was consistent across a number of tumour cell lines tested, and was associated with modulation of Smad2/3 activation (Eberlein et al., unpublished data). The role of avb6 as a key activator of TGF-b activation in tissues is well described. 4, 23 This function can also be performed by avb8; 32,34 therefore, 264RAD could modify avb8-dependent TGF-b activation either in the tumour cells or in fibroblasts. However, in the Calu-3 (ITGB8 'high') and NCI-H358 (ITGB8 'low') 264RAD inhibits tumour growth C Eberlein et al cells the cross-talk was avb6 dependent, as small interfering RNA to b6 completely inhibited tumour cell activation of a-SMA. This does not exclude a role for b8, but does suggest that the initiating event is largely b6 dependent.
The anti-tumour effects of 264RAD were more apparent in vivo. In Detroit 562 we show that 264RAD influences both tumour cell proliferation and activation of stromal cells. 264RAD gave modest (30%) inhibition of Detroit 562 growth in vitro (data not shown); however, biomarker analysis performed on treated tumours revealed marked inhibition of pERK and Ki67 in the tumour cells. 264RAD also downregulated avb6 expression in the tumour cells, consistent with observations that 264RAD drives receptor internalisation in vitro (unpublished data). We also observed a reciprocal increase in E-cadherin expression in those regions where avb6 expression was reduced, consistent with the association of avb6 expression with epithelial-mesenchymal transition, and driving the downregulation of E-cadherin expression. 9 Although in tumours taken at the end of study no change in Smad phosphorylation was detected, modulation of both FN and a-SMA expression, both TGF-b-mediated proteins was observed, 39, 40 suggesting modulation of TGF-b-dependent signalling in the stroma. From these data we conclude that 264RAD inhibits tumour cell growth by targeting both tumour proliferation signals and modulating activated stroma. Detroit 562 cells express both b6 and b8 mRNA, but we have been unable to determine whether 264RAD modulates tumour growth purely through avb6, and it would be informative to understand whether avb8 also contributes to tumour growth in this model. avb6 and TGF-b regulate a number of processes involved in tumour progression and have a close functional relationship.
In tumour cells avb6 can activate ERK, 17 increase protease expression, 14, 16, 17 modulate epithelial-mesenchymal transition status 9 and promote an invasive phenotype, 16, 18, 20 whereas in the context of the tumour microenvironment avb6 can induce a tumour-associated fibroblast phenotype. 19 TGF-b can suppress or promote growth, depending on cell context, drive epithelial À mesenchymal transition 43, 44 and activate cancer associated-fibroblasts. 19 Given the strong disease association for avb6 in a number of tumour types, identifying the key features of tumours likely to be dependent on avb6-mediated signalling is critical to understand where agents targeting avb6 will give benefit in established disease. Our data suggest that avb6 antagonists give single-agent activity in tumours that are dependent on TGF-b. Interestingly features that confer TGF-b dependency have been suggested, such as downregulation of disabled homolog 2 43 or an association with ras or raf mutation. 44 Increased avb6 expression is associated with increased invasion and metastasis, expression at the invasive edge being associated with increased protease activity. 264RAD inhibited lung metastasis in vivo in the metastatic 4T1 murine breast orthotopic model. Demonstrating modulation of both primary the tumours and the incidence of metastatic deposits suggest that 264RAD could retard tumour cell invasion and dissemination. To our knowledge this is the first time a therapeutic targeting avb6 has been shown to inhibit distant metastasis. Although 4T1 are strongly positive for avb6 integrin, the mRNA Itgb8 is also expressed. Owing to a lack of suitable antibodies we were unable to confirm protein expression. Therefore it is not possible to exclude that avb8 forms part of this signalling complex. Interestingly, 4T1 tumour growth is also sensitive to TGF-b sequestration 45 and Alk-5 inhibition Given tumour models express ITGB8, we cannot exclude the possibility that the inhibition of avb8 by 264RAD contributes to anti-tumour activity, even though we have not demonstrated a role for avb8 in vitro. The role of avb8 in epithelial tumour cell biology is poorly understood. Increased expression of avb8 is reported to negatively regulate the growth of SW480 cells. 35 In U87 MG cells downregulation of b8 by microRNA-93 is associated with increased angiogenesis and tumour growth, while cells overexpressing the integrin show increased apoptosis. 46 Owing to the lack of antibodies to b8 integrin we do not know the expression of the integrin in our pre-clinical models. There is a correlation between avb6 expression and avb8 at the mRNA level in tumour array data; however, this type of disease expression analysis is complicated by the expression of avb8 on activated fibroblasts. 46 Interestingly, b8 expression has been associated with a metastatic breast signature, which suggests that it may make a positive contribution to epithelial tumour progression. 47, 48 In some tumours avb6 and avb8 may therefore cooperate to promote tumour growth and dissemination. Further exploration of the role of avb8 in solid tumour biology is warranted. In the current studies we have assessed the effects of 264RAD using xenografted tumour models. Given the complexity of the biology and the limitations of xenograft tumour models it will be interesting to test 264RAD in murine transgenic or human-derived explant models that may recapitulate relevant tumour biology more faithfully. 49 In summary, we have generated a therapeutic antibody with the unique property of targeting avb6 integrin with some activity versus avb8 integrin. This antibody has potential to continue to be developed as a therapeutic, treating tumours dependent on avb6 for growth and invasion.
MATERIALS AND METHODS
Immunisation and antibody generation
Antibodies to avb6 were generated as described in US patent Application Serial number 08/759,620 and International Patent Applications WO98/ 24893 and WO00/76310. Xenomouse animals were immunised with Chinese hamster ovary cells overexpressing avb6 integrin. Spleens were harvested from the mice showing the strongest titres and hybridomas generated by B cell fusion with myeloma P3 Â 63Ag8.653 cells purchased from ATCC (cat#CRL1580) (Manassas, VA, USA). Control human IgG1 antibody was generated at MedImmune (Cambridge, UK).
Reagents
Collagen I-coated 96-well plates were obtained from BD Biosciences (Oxford UK). avb6 antibody (10D5) and avb3 antibody (LM609) were obtained from Merck and Millipore (Darmstadt, Germany); avb5 antibody (P5H9) and a4 antibody (7.2R) from R&D Systems (Abingdon, UK); av antibody (L230) from Alexis (Exeter, UK); a5 antibody (IIA1) from BD Biosciences (Oxford, UK). Goat Anti-Human, Alexa Fluor 488 from Invitrogen (Paisley, UK); mouse anti a-smooth muscle actin antibody (1A4) from Sigma (Dorset, UK); and ELISA kit for MMP-9 from R&D Systems (Abingdon, UK).
Cell culture and stable cell lines
Normal human dermal fibroblasts were purchased from PromoCell, cultured in PromoCell fibroblast growth media PromoCell (Heidelberg, Germany) and maintained at 5% CO 2 at 37 1C. A549, 4T1, Detroit 562, Calu-3, MDA-MB-231, MDA-MB-468, NCI-H2122, NCI-H1299 and NCI-H358 cells were obtained from ATCC. Colo205 and HT-29 cells were obtained from the ECACC. No further authentication was performed. Human, murine and cynomolgus av and b6 genes were cloned into pCR3.1 to generate K562 cell lines stably expressing human, murine or cynomolgus avb6. Human av and b8 genes were cloned into pGenIRES constructs to create K562 cells stably expressing avb8. All cell lines were passaged for no longer than 3 months, cultured in RPMI media supplemented with 10% serum and 2 mM L-glutamine and maintained in 5% CO 2 at 37 1C.
Cell adhesion assays
Detailed methods for all cell adhesion assays are shown in Supplementary Methods. Briefly, for each cell adhesion 96-well assay plates were coated with ligands at the appropriate concentration and blocked with phosphate-buffered saline (PBS) containing 3% bovine serum albumin (BSA). As required, cells were trypsinised to take them into suspension. All cells were then allowed to adhere to ligand-coated plates, in the presence and absence of function-blocking antibodies in Hank's balanced salt solution containing 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 2 mM MgCl 2 and 0.5 mM CaCl 2 at 37 1C, 5% CO 2 for 30-60 min. K562 cells were allowed to adhere in the presence of 1 mM MnCl 2 . Plates were then washed in PBS, fixed in ethanol and binding visualised by staining with crystal violet, solubilised in 0.1% Triton X-100 and read at optical density 570 nm.
Integrin profiling capture assays 
FACS-based binding assays
The relative binding of 264RAD to human avb6 and avb8 and to murine and cynomolgus avb6 was measured using FACS. Cells were harvested and resuspended at 2 Â 10 6 cells/ml in ice-cold PBS/1% BSA containing 2 mM MgCl 2 and 0.5 mM CaCl 2 . Two hundred microltres of cell suspension was incubated with dilutions of either 264RAD or IgG1 isotype control in FACS tubes BD Biosciences, for 1 h on ice. The cells were washed with 4 ml of PBS/1% BSA, and incubated with 200 ml of PBS/1% BSA containing 10 mg/ml of goat anti-human, Alexa 488 antibody at 4 1C for 30 min and washed as above. Cells were finally resuspended in 500 ml of PBS and binding of 264RAD measured using a FACS Calibur BD Biosciences. ) in a-MEM (200 ml) were added to the Matrigel and 0.5 ml fetal calf serum containing a-MEM placed in the lower chamber. The Transwell was incubated at 37 1C. After 72 h, cells that had invaded to the bottom were collected as follows. The 0.5 ml of media in the lower chamber was collected and placed in 9 ml of filtered Isoton (BD Biosciences). Trypsin-EDTA (0.5 ml) was added to the lower chamber and incubated at 37 1C (45 min), the insert agitated to release cells attached to its under-surface and then removed to the same Isoton suspension. The total 10-ml cell suspension was counted on a Casy 1 cell counter (Sharfe System GmbH, Reutlingen, Germany). Results were expressed relative to the invasion of control treatments. In some experiments avb6-blocking 264RAD or control antibody (human IgG1) was added (10 mg/ml) to cells for 30 min at 4 1C prior to cell plating onto Matrigel.
MMP-9 protease expression assay
Calu-3 cells were seeded on collagen-I-coated 96-well tissue culture plates at 7500 cells per well in RPMI supplemented with 10% fetal calf serum. Cells were incubated in the presence of 264RAD or control human IgG1 for 7 days at 37 1C. Condition media was then harvested and analysed for the presence of MMP-9 by ELISA.
Normal human dermal fibroblasts/tumour cell co-culture assays Normal human dermal fibroblasts were seeded on collagen I-coated 96-well plates at 2000 cells per well in PromoCell fibroblast growth media. Following 3 days incubation at 37 1C, 5% CO 2, the media was aspirated from the wells and tumour cells seeded onto the normal human dermal fibroblasts monolayer at 1000 cells per well in 100 ml of RPMI, 10% fetal calf serum, 2 mM L-glutamine per well. The following day the antibody was added in RPMI, 2% fetal calf serum, 2 mM L-glutamine. Fresh media and antibody were added after 4 days incubation at 37 1C, 5% CO 2 . After a total of 8 days cells were fixed with 4% formaldehyde solution in PBS containing 0.1% Triton X-100 for 30 min at RT and then washed with PBS and blocked for 1 h at 37 1C with PBS/1% BSA. The cells were incubated with a-SMA antibody diluted 1 in 2000 in PBS/0.05% Tween 20/1%BSA for 1 h at 37 1C. Cells were then washed and incubated with PBS/1%BSA containing 4 mg/ml anti-human Alexa 488 antibody and 1 mg/ml Hoechst 33342 Stain for 30 min at 37 1C. The plates were washed twice with PBS and imaged on the Cellomics Arrayscan.
Anti-tumour activity studies
The detailed method is shown in Supplementary Methods. All mice were maintained in accordance with specific institutional guidelines. Detroit 562 human tumour xenografts were established in female athymic mice by subcutaneous implantation into the hind flank. Mice were randomised into groups of 15 when tumours reached a volume of B0.1 cm 3 . 4T1 syngeneic tumours were established in Balb-C mice by orthotopic implantation into the mammary fat pad. Groups of 12-14 were dosed 24 h post cell implantation. 264RAD or vehicle was administered intraperitoneally as indicated for each experiment. Tumour volumes were assessed twice weekly. Statistical significance was evaluated using a one-tailed two-sample t-test. Tumours and lungs (4T1 studies only) were collected into buffered formalin on the day of study termination and processed to paraffin block for histological evaluation.
Immunohistochemistry PD analysis
Detailed methods for each analysis are provided in Supplementary Methods. Briefly, immunohistochemistry analysis was performed on 
Metastatic tumour analysis
To assess the number of lung metastases in the 4T1 study, following formalin fixation each lobe was sectioned, five serial sections per lobe, 200 mm apart. The sections were then stained with hematoxylin and eosin stain and the number of metastases counted using light microscopy.
ABBREVIATIONS a-SMA, alpha smooth muscle actin; GST, glutathione-S-transferase; MVD, microvessel density; MVA, microvessel area; TGF-b LAP, transforming growth factor b latency-associated peptide.
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